Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00970073 · ClinicalTrials.gov registry record · NA
Low Dose Thymoglobulin to Protect Kidney Function After Liver Transplant
A NA study, sponsored by The Cleveland Clinic.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT00970073: Completed NA study, sponsored by The Cleveland Clinic.
NCT00970073 is a NA study that has completed, run by The Cleveland Clinic. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00970073, a NA study, has completed, sponsored by The Cleveland Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
This study will evaluate the use of a drug called Thymoglobulin, combined with a delayed start of the anti-rejection drugs (10 days after liver transplant), compared to the current approach of starting anti-rejection drugs called calcineurin inhibitors or CNI's within 2 days after the liver transplant.
Primary Outcome
Postoperative acute kidney injury is measured as reduced (eGFR) within 12 months post-surgery.
Interventions
- DRUG Mycophenolate mofetil
- BIOLOGICAL Thymoglobulin 3mg total
- BIOLOGICAL Thymoglobulin 4.5mg total
- DRUG tacrolimus 3-8
- DRUG tacrolimus 8-12
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2009-08 |
| Est. Completion | 2015-12 |
| Phase | NA |
What the finished NCT00970073 record still lists
NCT00970073 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 5 interventions - of which Mycophenolate mofetil is the first listed.
NCT00970073 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00970073 about?
NCT00970073 is a clinical study titled "Low Dose Thymoglobulin to Protect Kidney Function After Liver Transplant". This study will evaluate the use of a drug called Thymoglobulin, combined with a delayed start of the anti-rejection drugs (10 days after liver transplant), compared to the current approach of starting anti-rejection drugs called calcineurin inhibitors or CNI's within 2 days after the liver transpla...
What is the current status of trial NCT00970073?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2009-08. Estimated completion is 2015-12.
What interventions are being tested in trial NCT00970073?
The interventions under investigation include: Mycophenolate mofetil (DRUG), Thymoglobulin 3mg total (BIOLOGICAL), Thymoglobulin 4.5mg total (BIOLOGICAL), tacrolimus 3-8 (DRUG), tacrolimus 8-12 (DRUG).
Who is sponsoring clinical trial NCT00970073?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00970073's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia